The effectiveness and safety of oral Chinese patent medicines in treating myocardial infarction complicated with heart failure: a network meta-analysis of 12 interventions
Frontiers in Cardiovascular Medicine · 21.05.2026 · 13
DOI: 10.3389/fcvm.2026.1832017 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 21.05.2026. Verfasst von Yiying Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China. Die Arbeit nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Objective
To systematically evaluate the effectiveness of different oral Chinese patent medicines (CPMs) combined with conventional treatment (CT) in the treatment of myocardial infarction with heart failure (MI-HF) using a Bayesian network Meta-analysis.
Methods
Computerized searches were conducted in CNKI, WanFang, VIP, SinoMed, PubMed, EMbase, Web of Science, and the Cochrane Library for relevant randomized controlled trials (RCTs) published from database inception until October 15, 2025. The quality of the included studies was assessed using the Cochrane Risk of Bias tool (RoB2). Statistical analysis was performed using Stata 17.0 and RevMan 5.3.
Results
A total of 42 RCTs were included, involving 12 oral CPMs, 6 outcome indicators and adverse reactions. In terms of improving the total clinical effective rate, Yixinshu capsules demonstrated the best therapeutic effect. Xintong oral liquid showed the best effect in improving LVEF and reducing LVESD. For reducing LVEDD, Shexiang Baoxin pill was optimal. Guanxin Shutong capsules were the most effective for lowering NT-proBNP and increasing the 6 MWT distance.
Conclusion
Oral CPMs combined with CT significantly improve cardiac function, ventricular remodeling, and exercise tolerance in MI-HF. While short-term tolerability is favorable, poor reporting limits definitive safety conclusions. Notably, Xintong Oral Liquid, Guanxin Shutong Capsules, and Qili Qiangxin Capsules exhibit the most outstanding comprehensive benefits. Systematic Review Registration https://www.crd.york.ac.uk/PROSPERO/ , PROSPERO CRD420251234570.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
- Graduate School of Beijing University of Chinese Medicine, Beijing, China.
- Department of Rheumatology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
- Department of Nephrology and Endocrinology, Yuquan Hospital, Tsinghua University, Beijing, China.
- School of Medicine, Tsinghua University, Beijing, China.
Zitieren
APA
Liu, Y., Liu, R., Yang, K., Li, J., Ye, G., Huang, X., Tao, S., Xue, T., & Yuan, Y. (2026). The effectiveness and safety of oral Chinese patent medicines in treating myocardial infarction complicated with heart failure: a network meta-analysis of 12 interventions. Frontiers in Cardiovascular Medicine, 13. https://doi.org/10.3389/fcvm.2026.1832017
Vancouver
Liu Y, Liu R, Yang K, Li J, Ye G, Huang X, et al. The effectiveness and safety of oral Chinese patent medicines in treating myocardial infarction complicated with heart failure: a network meta-analysis of 12 interventions. Frontiers in Cardiovascular Medicine. 2026;13. doi:10.3389/fcvm.2026.1832017
BibTeX
@article{Liu2026,
author = {Liu, Yiying and Liu, Ruikang and Yang, Kai and Li, Jun and Ye, Guancheng and Huang, Xuanchun and Tao, Shiyi and Xue, Tiantian and Yuan, Yulian},
title = {The effectiveness and safety of oral Chinese patent medicines in treating myocardial infarction complicated with heart failure: a network meta-analysis of 12 interventions},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fcvm.2026.1832017}
}
EUVIMED